Literature DB >> 35121946

Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment.

Nida Pasha1, Nicholas C Turner2,3.   

Abstract

Rational development of targeted therapies has revolutionized metastatic breast cancer outcomes, although resistance to treatment remains a major challenge. Advances in molecular profiling and imaging technologies have provided evidence for the impact of clonal diversity in cancer treatment resistance, through the outgrowth of resistant clones. In this Review, we focus on the genomic processes that drive tumoral heterogeneity and the mechanisms of resistance underlying metastatic breast cancer treatment and discuss implications for future treatment strategies.
© 2021. Springer Nature America, Inc.

Entities:  

Mesh：

Year:  2021        PMID： 35121946     DOI： 10.1038/s43018-021-00229-1

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


  153 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

Authors:  Seock-Ah Im; Yen-Shen Lu; Aditya Bardia; Nadia Harbeck; Marco Colleoni; Fabio Franke; Louis Chow; Joohyuk Sohn; Keun-Seok Lee; Saul Campos-Gomez; Rafael Villanueva-Vazquez; Kyung-Hae Jung; Arunava Chakravartty; Gareth Hughes; Ioannis Gounaris; Karen Rodriguez-Lorenc; Tetiana Taran; Sara Hurvitz; Debu Tripathy
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 4.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

5.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Authors:  Sandra M Swain; David Miles; Sung-Bae Kim; Young-Hyuck Im; Seock-Ah Im; Vladimir Semiglazov; Eva Ciruelos; Andreas Schneeweiss; Sherene Loi; Estefanía Monturus; Emma Clark; Adam Knott; Eleonora Restuccia; Mark C Benyunes; Javier Cortés
Journal:  Lancet Oncol       Date:  2020-03-12       Impact factor: 41.316

6.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

7.  Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases.

Authors:  Zheng Hu; Zan Li; Zhicheng Ma; Christina Curtis
Journal:  Nat Genet       Date:  2020-05-18       Impact factor: 38.330

8.  Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.

Authors:  Jennifer L Caswell-Jin; Sylvia K Plevritis; Lu Tian; Christopher J Cadham; Cong Xu; Natasha K Stout; George W Sledge; Jeanne S Mandelblatt; Allison W Kurian
Journal:  JNCI Cancer Spectr       Date:  2018-12-24

9.  The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.

Authors:  Ben O'Leary; Rosalind J Cutts; Yuan Liu; Sarah Hrebien; Xin Huang; Kerry Fenwick; Fabrice André; Sibylle Loibl; Sherene Loi; Isaac Garcia-Murillas; Massimo Cristofanilli; Cynthia Huang Bartlett; Nicholas C Turner
Journal:  Cancer Discov       Date:  2018-09-11       Impact factor: 39.397

10.  Clonal evolution in breast cancer revealed by single nucleus genome sequencing.

Authors:  Yong Wang; Jill Waters; Marco L Leung; Anna Unruh; Whijae Roh; Xiuqing Shi; Ken Chen; Paul Scheet; Selina Vattathil; Han Liang; Asha Multani; Hong Zhang; Rui Zhao; Franziska Michor; Funda Meric-Bernstam; Nicholas E Navin
Journal:  Nature       Date:  2014-07-30       Impact factor: 49.962
View more
  7 in total

1.  New classification for advanced breast cancer patients experiencing disease progression during salvage treatment: a single-center retrospective cohort study.

Authors:  Jiahuai Wen; Liping Ren; Wenxia Li; Junhong Li; Lezhen Huang; Zhongyu Yuan; Qianjun Chen
Journal:  Ann Transl Med       Date:  2022-05

2.  Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer.

Authors:  Hanwen Wang; Chen Zhao; Cesar A Santa-Maria; Leisha A Emens; Aleksander S Popel
Journal:  iScience       Date:  2022-06-30

3.  Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.

Authors:  Lale Umutlu; Julian Kirchner; Nils-Martin Bruckmann; Janna Morawitz; Gerald Antoch; Saskia Ting; Ann-Kathrin Bittner; Oliver Hoffmann; Lena Häberle; Eugen Ruckhäberle; Onofrio Antonio Catalano; Michal Chodyla; Johannes Grueneisen; Harald H Quick; Wolfgang P Fendler; Christoph Rischpler; Ken Herrmann; Peter Gibbs; Katja Pinker
Journal:  Cancers (Basel)       Date:  2022-03-29       Impact factor: 6.575

4.  Characterisation of 3D Bioprinted Human Breast Cancer Model for In Vitro Drug and Metabolic Targeting.

Authors:  Titanilla Dankó; Gábor Petővári; Regina Raffay; Dániel Sztankovics; Dorottya Moldvai; Enikő Vetlényi; Ildikó Krencz; András Rókusz; Krisztina Sipos; Tamás Visnovitz; Judit Pápay; Anna Sebestyén
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

5.  LncRNA-Based Classification of Triple Negative Breast Cancer Revealed Inherent Tumor Heterogeneity and Vulnerabilities.

Authors:  Radhakrishnan Vishnubalaji; Ramesh Elango; Nehad M Alajez
Journal:  Noncoding RNA       Date:  2022-06-21

Review 6.  The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets.

Authors:  Guang Yang; Tao Lu; Daniel J Weisenberger; Gangning Liang
Journal:  Genes (Basel)       Date:  2022-08-29       Impact factor: 4.141

7.  Stat3 Tyrosine 705 and Serine 727 Phosphorylation Associate With Clinicopathological Characteristics and Distinct Tumor Cell Phenotypes in Triple-Negative Breast Cancer.

Authors:  Michaela Stenckova; Rudolf Nenutil; Borivoj Vojtesek; Philip J Coates
Journal:  Pathol Oncol Res       Date:  2022-08-09       Impact factor: 2.874
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.